90 related articles for article (PubMed ID: 9258118)
1. Intravesical therapy with vinorelbine tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder.
Bonfil RD; Russo DM; Schmilovich AJ; Garcia-Palazzo IB
J Urol; 1997 Sep; 158(3 Pt 1):912-5. PubMed ID: 9258118
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
3. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
[TBL] [Abstract][Full Text] [Related]
4. Exposure to vinorelbine inhibits in vitro proliferation and invasiveness of transitional cell bladder carcinoma.
Bonfil RD; Russo DM; Schmilovich AJ
J Urol; 1996 Aug; 156(2 Pt 1):517-21. PubMed ID: 8683728
[TBL] [Abstract][Full Text] [Related]
5. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
6. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
7. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
8. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.
Bonfil RD; Russo DM; Binda MM; Delgado FM; Vincenti M
Urol Oncol; 2002; 7(4):159-66. PubMed ID: 12474532
[TBL] [Abstract][Full Text] [Related]
9. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice.
Mengs U; Schwarz T; Bulitta M; Weber K
Anticancer Res; 2000; 20(5B):3565-8. PubMed ID: 11131663
[TBL] [Abstract][Full Text] [Related]
12. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
13. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
14. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
15. Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed.
Khandaker MH; Kadhim SA; Ichim TE; Howson-Jan K; Chin J; Singhal SK
Anticancer Res; 2000; 20(1A):183-9. PubMed ID: 10769653
[TBL] [Abstract][Full Text] [Related]
16. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer.
Le Visage C; Rioux-Leclercq N; Haller M; Breton P; Malavaud B; Leong K
J Urol; 2004 Mar; 171(3):1324-9. PubMed ID: 14767342
[TBL] [Abstract][Full Text] [Related]
18. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
19. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
[TBL] [Abstract][Full Text] [Related]
20. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]